Evaluation of Crohn's Disease Small-Bowel Mucosal Healing Using Capsule Endoscopy and Usefulness of Leucine-Rich α2-Glycoprotein
- PMID: 36832114
- PMCID: PMC9955912
- DOI: 10.3390/diagnostics13040626
Evaluation of Crohn's Disease Small-Bowel Mucosal Healing Using Capsule Endoscopy and Usefulness of Leucine-Rich α2-Glycoprotein
Abstract
Recently, the importance of achieving clinical and deep remissions with mucosal healing (MH) has been demonstrated as a therapeutic goal to avoid Crohn's disease (CD) surgical operations. Although ileocolonoscopy (CS) is considered the gold standard, there are increasing reports on the benefits of capsule endoscopy (CE) and serum leucine-rich α2-glycoprotein (LRG) for evaluating small-bowel lesions in CD. We evaluated the data of 20 patients with CD who underwent CE in our department between July 2020 and June 2021 and whose serum LRG level was measured within 2 months. Concerning the mean LRG value, there was no significant difference between the CS-MH and CS-non-MH groups. Conversely, the mean LRG level was 10.0 μg/mL in seven patients in the CE-MH group and 15.2 μg/mL in 11 patients in the CE-non-MH group with a significant difference between the two groups (p = 0.0025). This study's findings show that CE can sufficiently determine total MH in most cases, and LRG is useful for evaluating CD small-bowel MH because of its correlation with CE-MH. Furthermore, satisfying CS-MH criteria and a cut-off value of 13.4 μg/mL for LRG suggests its usefulness as a CD small-bowel MH marker, which could be incorporated into the treat-to-target strategy.
Keywords: Crohn’s disease; capsule endoscopy; leucine-rich α2-glycoprotein; mucosal healing; small-bowel.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a Surrogate Marker of Small Bowel Mucosal Injury in Crohn's Disease.Inflamm Intest Dis. 2023 Jul 10;8(2):69-76. doi: 10.1159/000531622. eCollection 2023 Oct. Inflamm Intest Dis. 2023. PMID: 37901342 Free PMC article.
-
Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn's Disease.Inflamm Intest Dis. 2023 May 11;8(1):13-22. doi: 10.1159/000530825. eCollection 2023 Jan-Dec. Inflamm Intest Dis. 2023. PMID: 37404381 Free PMC article.
-
Monitoring of leucine-rich alpha-2-glycoprotein and assessment by small bowel capsule endoscopy are prognostic for Crohn's disease patients.JGH Open. 2023 Sep 5;7(9):645-651. doi: 10.1002/jgh3.12964. eCollection 2023 Sep. JGH Open. 2023. PMID: 37744712 Free PMC article.
-
Capsule Endoscopy in Crohn's Disease-From a Relative Contraindication to Habitual Monitoring Tool.Diagnostics (Basel). 2021 Sep 22;11(10):1737. doi: 10.3390/diagnostics11101737. Diagnostics (Basel). 2021. PMID: 34679435 Free PMC article. Review.
-
Clinical Practice Guidelines for the Use of Video Capsule Endoscopy.Gastroenterology. 2017 Feb;152(3):497-514. doi: 10.1053/j.gastro.2016.12.032. Epub 2017 Jan 4. Gastroenterology. 2017. PMID: 28063287 Review.
Cited by
-
Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.Biomedicines. 2024 Jul 8;12(7):1520. doi: 10.3390/biomedicines12071520. Biomedicines. 2024. PMID: 39062093 Free PMC article. Review.
-
Significance of Serum Leucine-rich Alpha-2 Glycoprotein as a Diagnostic Marker in Pediatric Inflammatory Bowel Disease.Kobe J Med Sci. 2024 Jan 24;69(4):E122-E128. doi: 10.24546/0100486228. Kobe J Med Sci. 2024. PMID: 38379274 Free PMC article.
-
Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn's disease during biological remission.Intest Res. 2025 Apr;23(2):170-181. doi: 10.5217/ir.2024.00042. Epub 2024 Aug 19. Intest Res. 2025. PMID: 39155217 Free PMC article.
-
Serum Leucine-Rich α2 Glycoprotein Could Be a Useful Biomarker to Differentiate Patients with Normal Colonic Mucosa from Those with Inflammatory Bowel Disease or Other Forms of Colitis.J Clin Med. 2024 May 17;13(10):2957. doi: 10.3390/jcm13102957. J Clin Med. 2024. PMID: 38792498 Free PMC article.
References
-
- Turner D., Ricciuto A., Lewis A., D’Amico F., Dhaliwal J., Griffiths A.M., Bettenworth D., Sandborn W.J., Sands B.E., Reinisch W., et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in inflammatory bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570–1583. doi: 10.1053/j.gastro.2020.12.031. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous